No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Private biotechs and novel targets head for human trials
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
